Concomitant lethal mutagenesis of human immunodeficiency virus type 1

Journal of Molecular Biology

Volumn 419, Issue 3-4, 2012, Pages 158-170

  Dapp, Michael J ^a,b,c,d   Holtz, Colleen M ^a,b   Mansky, Louis M ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

deamination; evolution; lentivirus; retrovirus; transversion

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; AZACITIDINE; VIRUS VECTOR;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; GENE INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENE; VIRUS INFECTIVITY; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; RNA VIRUSES;

EID: 84860782445     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.03.003     Document Type: Article

References (65)

1. Eigen M. Viral quasispecies Sci. Am. 269 1993 42 49
2. Bull J.J., Meyers L.A., and Lachmann M. Quasispecies made simple PLoS Comput. Biol. 1 2005 e61
3. Crotty S., Cameron C.E., and Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin Proc. Natl Acad. Sci. USA 98 2001 6895 6900 (Pubitemid 32538313)
4. Graci J.D., and Cameron C.E. Therapeutically targeting RNA viruses via lethal mutagenesis Future Virol. 3 2008 553 566
5. Anderson J.P., Daifuku R., and Loeb L.A. Viral error catastrophe by mutagenic nucleosides Annu. Rev. Microbiol. 58 2004 183 205 (Pubitemid 39551984)
6. Smith R.A., Loeb L., and Preston B.D. Lethal mutagenesis of HIV Virus Res. 107 2005 215 228 (Pubitemid 40093094)
7. Dapp M.J., Clouser C.L., Patterson S., and Mansky L.M. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1 J. Virol. 83 2009 11950 11958
8. Sierra S., Davila M., Lowenstein P.R., and Domingo E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity J. Virol. 74 2000 8316 8323 (Pubitemid 30666681)
9. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., and Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system J. Virol. 76 2002 8505 8517 (Pubitemid 34864045)
10. Harris K.S., Brabant W., Styrchak S., Gall A., and Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis Antiviral Res. 67 2005 1 9 (Pubitemid 40798912)
11. Mullins J.I., Heath L., Hughes J.P., Kicha J., Styrchak S., and Wong K.G. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461 PloS One 6 2011 e15135
12. Cuevas J.M., Gonzalez-Candelas F., Moya A., and Sanjuan R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo J. Virol. 83 2009 5760 5764
13. Lutchman G., Danehower S., Song B.C., Liang T.J., Hoofnagle J.H., Thomson M., and Ghany M.G. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy Gastroenterology 132 2007 1757 1766 (Pubitemid 46677946)
14. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., and Watt I.N. DNA deamination mediates innate immunity to retroviral infection Cell 113 2003 803 809 (Pubitemid 36724943)
15. Lecossier D., Bouchonnet F., Clavel F., and Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein Science 300 2003 1112 (Pubitemid 36583087)
16. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99 103 (Pubitemid 36834849)
17. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94 98 (Pubitemid 36834848)
18. Turelli P., Mangeat B., Jost S., Vianin S., and Trono D. Inhibition of hepatitis B virus replication by APOBEC3G Science 303 2004 1829 (Pubitemid 38374868)
19. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., and Narvaiza I. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons Curr. Biol.: CB 16 2006 480 485 (Pubitemid 43343708)
20. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins Curr. Biol.: CB 14 2004 1392 1396 (Pubitemid 39081643)
21. Sasada A., Takaori-Kondo A., Shirakawa K., Kobayashi M., Abudu A., and Hishizawa M. APOBEC3G targets human T-cell leukemia virus type 1 Retrovirology 2 2005 32
22. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., and Bollman B. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif Cell 114 2003 21 31 (Pubitemid 36859838)
23. Zennou V., and Bieniasz P.D. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates Virology 349 2006 31 40
24. Albin J.S., and Harris R.S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics Expert Rev. Mol. Med. 12 2010 e4
25. Rosenberg B.R., and Papavasiliou F.N. Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection Adv. Immunol. 94 2007 215 244 (Pubitemid 46856612)
26. Delebecque F., Suspene R., Calattini S., Casartelli N., Saib A., and Froment A. Restriction of foamy viruses by APOBEC cytidine deaminases J. Virol. 80 2006 605 614 (Pubitemid 43062873)
27. Harris R.S., and Liddament M.T. Retroviral restriction by APOBEC proteins Nat. Rev., Immunol. 4 2004 868 877 (Pubitemid 39490762)
28. Malim M.H., and Emerman M. HIV-1 accessory proteins - ensuring viral survival in a hostile environment Cell Host Microbe 3 2008 388 398 (Pubitemid 351784365)
29. Chiu Y.L., and Greene W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements Annu. Rev. Immunol. 26 2008 317 353 (Pubitemid 351600379)
30. Pace C., Keller J., Nolan D., James I., Gaudieri S., Moore C., and Mallal S. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation J. Virol. 80 2006 9259 9269 (Pubitemid 44359998)
31. Vazquez-Perez J.A., Ormsby C.E., Hernandez-Juan R., Torres K.J., and Reyes-Teran G. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression Retrovirology 6 2009 23
32. Browne E.P., Allers C., and Landau N.R. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent Virology 387 2009 313 321
33. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., and Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity J. Biol. Chem. 278 2003 44412 44416 (Pubitemid 37377191)
34. Bishop K.N., Holmes R.K., and Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination J. Virol. 80 2006 8450 8458 (Pubitemid 44384857)
35. Schumacher A.J., Hache G., Macduff D.A., Brown W.L., and Harris R.S. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction J. Virol. 82 2008 2652 2660 (Pubitemid 351329156)
36. Loeb L.A., Essigmann J.M., Kazazi F., Zhang J., Rose K.D., and Mullins J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs Proc. Natl Acad. Sci. USA 96 1999 1492 1497 (Pubitemid 29098478)
37. Sadler H.A., Stenglein M.D., Harris R.S., and Mansky L.M. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis J. Virol. 84 2010 7396 7404
38. Rogozin I.B., Babenko V.N., Milanesi L., and Pavlov Y.I. Computational analysis of mutation spectra Brief. Bioinform. 4 2003 210 227
39. Rogozin I.B., and Pavlov Y.I. Theoretical analysis of mutation hotspots and their DNA sequence context specificity Mutat. Res. 544 2003 65 85 (Pubitemid 36897770)
40. Kaminskas E., Farrell A.T., Wang Y.C., Sridhara R., and Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension Oncologist 10 2005 176 182 (Pubitemid 40463154)
41. Paces V., Doskocil J., and Sorm F. Incorporation of 5-azacytidine into nucleic acids of Escherichia coli Biochim. Biophys. Acta 161 1968 352 360
42. Li L.H., Olin E.J., Buskirk H.H., and Reineke L.M. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia Cancer Res. 30 1970 2760 2769
43. Rogstad D.K., Herring J.L., Theruvathu J.A., Burdzy A., Perry C.C., Neidigh J.W., and Sowers L.C. Chemical decomposition of 5-aza-2′- deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry Chem. Res. Toxicol. 22 2009 1194 1204
44. Jackson-Grusby L., Laird P.W., Magge S.N., Moeller B.J., and Jaenisch R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase Proc. Natl Acad. Sci. USA 94 1997 4681 4685
45. Pathak V.K., and Temin H.M. 5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate J. Virol. 66 1992 3093 3100
46. Cupples C.G., and Miller J.H. A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions Proc. Natl Acad. Sci. USA 86 1989 5345 5349 (Pubitemid 19185549)
47. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., and Palmer S. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome Nat. Struct. Mol. Biol. 11 2004 435 442 (Pubitemid 38568947)
48. Rausch J.W., Chelico L., Goodman M.F., and Le Grice S.F. Dissecting APOBEC3G substrate specificity by nucleoside analog interference J. Biol. Chem. 284 2009 7047 7058
49. Clouser C.L., Patterson S.E., and Mansky L.M. Exploiting drug repositioning for discovery of a novel HIV combination therapy J. Virol. 84 2010 9301 9309
50. Perales C., Agudo R., and Domingo E. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment PloS One 4 2009 e5554
51. Pariente N., Airaksinen A., and Domingo E. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus J. Virol. 77 2003 7131 7138 (Pubitemid 36666908)
52. Pariente N., Sierra S., Lowenstein P.R., and Domingo E. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors J. Virol. 75 2001 9723 9730 (Pubitemid 32900107)
53. Perales C., Agudo R., Tejero H., Manrubia S.C., and Domingo E. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections PLoS Pathog. 5 2009 e1000658
54. Perales C., Agudo R., Manrubia S.C., and Domingo E. Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus J. Mol. Biol. 407 2011 60 78
55. Mulder L.C., Harari A., and Simon V. Cytidine deamination induced HIV-1 drug resistance Proc. Natl Acad. Sci. USA 105 2008 5501 5506 (Pubitemid 351753892)
56. Kim E.Y., Bhattacharya T., Kunstman K., Swantek P., Koning F.A., Malim M.H., and Wolinsky S.M. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure J. Virol. 84 2010 10402 10405
57. Codoner F.M., Daros J.A., Sole R.V., and Elena S.F. The fittest versus the flattest: experimental confirmation of the quasispecies effect with subviral pathogens PLoS Pathog. 2 2006 e136
58. Sanjuan R., Cuevas J.M., Furio V., Holmes E.C., and Moya A. Selection for robustness in mutagenized RNA viruses PLoS Genet. 3 2007 e93
59. Levi L.I., Gnadig N.F., Beaucourt S., McPherson M.J., Baron B., Arnold J.J., and Vignuzzi M. Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds PLoS Pathog. 6 2010 e1001163
60. Pfeiffer J.K., and Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity Proc. Natl Acad. Sci. USA 100 2003 7289 7294 (Pubitemid 36706431)
61. Arribas M., Cabanillas L., and Lazaro E. Identification of mutations conferring 5-azacytidine resistance in bacteriophage Qbeta Virology 417 2011 343 352
62. Sierra M., Airaksinen A., Gonzalez-Lopez C., Agudo R., Arias A., and Domingo E. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe J. Virol. 81 2007 2012 2024 (Pubitemid 46214472)
63. Berkhout B., and van Hemert F.J. The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins Nucleic Acids Res. 22 1994 1705 1711 (Pubitemid 24155830)
64. Hache G., Liddament M.T., and Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain J. Biol. Chem. 280 2005 10920 10924 (Pubitemid 40418393)
65. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo Curr. Biol.: CB 14 2004 1385 1391 (Pubitemid 39081642)